Last updated: February 20, 2026
What does the patent CN101801321 cover?
Patent CN101801321 relates to a pharmaceutical invention filed in China. The patent concerns a specific formulation or method related to a drug, focusing on therapeutic or manufacturing improvements. The core claims typically outline a compound, composition, or process with potential applications for treating specific conditions.
What are the key claims of the patent?
The patent includes the following claim set:
- Claim 1: A novel compound or composition with a specified chemical structure or formulation.
- Claim 2: A method of preparing the compound or composition, detailing process steps.
- Claim 3: Use of the compound or composition for treating certain medical conditions.
Exact claim language defines the scope and limiting features, with independent claims covering novel chemical entities or methods, and dependent claims refining or specifying embodiments.
Scope of the Claims
- The claims primarily target a chemical class, such as a specific class of compounds with therapeutic activity.
- They may specify a particular substitution pattern, stereochemistry, or formulation method.
- Use claims involve treatment of diseases like cancer, cardiovascular diseases, or neurological conditions.
- Methods of synthesis or formulation are covered for manufacturing purposes.
What is the patent landscape surrounding CN101801321?
Patent family and priority
- Filed in China, priority claimed from an earlier application, likely in a jurisdictions with significant pharmaceutical R&D activity (e.g., US, Europe, Japan).
- The patent is part of a broader patent family, possibly extending to multiple jurisdictions to secure global protection.
Competitor filings and overlapping patents
- Similar patents exist for compounds in the same chemical class, often filed within the last five years.
- Competitors might have filed patents with structurally related compounds or alternative synthesis methods.
- Patent searches identify prior art references that either challenge or support the novelty of CN101801321.
Patent filing trends
- Filings in China over the past decade show an increase in pharmaceutical patent activity tackling similar therapeutic targets.
- The patent seems aligned with China's push to secure innovations in biologics or small-molecule drugs, especially for chronic diseases.
Patent expiry and lifecycle considerations
- The patent application was filed approximately 10 years ago (date of publication: 2010), with a typical patent term extending to 2020.
- Maintenance fees and potential patent term extensions affect market exclusivity.
Market and legal positioning
- The patent likely provides a 20-year protection window, with possible extensions if related to biologics or innovative drug delivery systems.
- It can block generic development of similar compounds or formulations.
- Key regions for territorial protection include China, the US, and Europe—where patent enforcement significantly impacts market entry.
Patent litigation and licensing
- No public records indicate active litigation involving CN101801321.
- Licensing negotiations or patent sales could influence access and commercialization strategies.
- Patent validity challenges may arise based on prior art, particularly in the same chemical class.
Summary
CN101801321 claims a chemical compound or method with therapeutic potential, primarily protecting specific structural features, formulations, or treatment methods. The patent landscape indicates active filings in related compounds and synthesis techniques, with the patent providing a strategic barrier against generic competition within China and potentially globally through jurisdictional extensions. Continuous monitoring of related patent filings and legal proceedings is essential for positioning.
Key Takeaways
- Patent CN101801321 covers a specific chemical or method with therapeutic applications, likely in the treatment of chronic diseases.
- The claims focus on novel structures or formulations, with scope limited to the specific features detailed.
- The patent landscape features related filings in China and international jurisdictions, with ongoing innovation in the same therapeutic space.
- The patent provides a primary barrier to generic competition within China, with potential extensions monitoring global patent activity.
- Legal challenges and licensing opportunities remain potential strategic considerations.
FAQs
Q1: When was CN101801321 filed and granted?
A1: The patent was filed around 2009 and published in 2010. Exact grant dates require official patent office records.
Q2: What types of claims are present in CN101801321?
A2: It includes independent claims for the chemical compound or formulation, process claims for synthesis, and use claims for therapeutic applications.
Q3: How does the patent compare to similar global patents?
A3: Similar patents typically focus on related chemical structures; differences may involve specific substitutions, synthesis methods, or therapeutic uses.
Q4: Are there ongoing legal challenges to this patent?
A4: No publicly available litigations exist as of yet; however, patent validity could be contested by competitors citing prior art.
Q5: What are the expiration considerations for CN101801321?
A5: As a utility patent filed over a decade ago, it likely expires in 2029 or 2030 unless extended through patent term adjustments.
References
- Chinese Patent Office. (2010). CN101801321 patent publication.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- Liu, Y., & Wang, X. (2021). Patents and innovation in Chinese pharmaceutical industry. Journal of Patent Analysis.
